Methods for producing enteroendocrine cells that make and secrete insulin
View Patent ↗Methods are described for producing enteroendocrine cells that make and secrete insulin in a mammal by blocking the expression or biological activity of one or more Foxo proteins or biologically active fragments or variants thereof.
1. A method for treating diabetes in a mammal, comprising administering to the mammal a therapeutically effective amount of an inhibitory oligonucleotide sufficiently complementary to an mRNA encoding Foxo1 to reduce its expression, wherein administering comprises delivering the inhibitory oligonucleotide to enteroendocrine progenitor cells in the mammal to produce glucose-responsive enteroendocrine cells that make and secrete insulin, and wherein the inhibitory oligonucleotide is orally administered in an enteric form so as to release the therapeutically effective amount in a gut region comprising enteroendocrine progenitor cells or is locally administered directly into or onto the gut region.
2. The method of claim 1 , wherein the inhibitory oligonucleotide is selected from the group consisting of an antisense RNA, an antisense DNA and a chimeric antisense DNA/RNA.
3. The method of claim 1 , wherein the inhibitory oligonucleotide is selected from the group consisting of small interfering RNA (siRNA) and small hairpin RNA (shRNA).
4. The method of claim 1 , wherein the diabetes is diabetes type 1.
5. The method of claim 1 , wherein the therapeutically effective amount is an amount that produces an effect selected from the group consisting of an increase in glucose responsiveness, an increase in serum insulin and the generation of enteroendocrine cells in the gastrointestinal tract that produce and secrete insulin.
6. The method of claim 1 , wherein the gut region is the duodenum, ileum or colon.
7. A method for producing enteroendocrine cells that make and secrete insulin in a mammal, comprising administering to the mammal an inhibitory oligonucleotide sufficiently complementary to mRNA encoding Foxo1 to reduce its expression, wherein administering comprises delivering the inhibitory oligonucleotide to enteroendocrine progenitor cells in the mammal in an amount to produce glucose-responsive enteroendocrine cells that make and secrete insulin, and wherein the inhibitory oligonucleotide is orally administered in an enteric form so as to release said therapeutically effective amount in a gut region of the mammal that comprises enteroendocrine progenitor cells or is locally administered directly into or onto the gut region.
8. The method of claim 7 , wherein the inhibitory oligonucleotide is selected from the group consisting of an antisense RNA, an antisense DNA and a chimeric antisense DNA/RNA.
9. The method of claim 7 , wherein the inhibitory oligonucleotide is selected from the group consisting of small interfering RNA (siRNA) and small hairpin RNA (shRNA).
10. The method of claim 7 , wherein the insulin-producing enteroendocrine cells further produce one or more pancreatic hormones selected from the group consisting of glucagon, pancreatic polypeptide, glucokinase, and glucose transport 2 (glut2), in response to administration of the inhibitory oligonucleotide.
11. The method of claim 7 , wherein the insulin-producing enteroendocrine cells also produce one or more proteins selected from the group consisting of prohormone-convertase 2 (Pc2), pancreatic and duodenal homeobox1 (Pdx1), MafA, Nkx6.1, Nkx2.2, and paired box gene 4 (Pax4).
12. The method of claim 7 , wherein the gut region is the duodenum, ileum or colon.
13. A method for making insulin-producing enteroendocrine cells comprising
a) isolating a population of non-insulin producing enteroendocrine progenitor cells from a gut region of a mammal,
b) contacting the population with an oligonucleotide sufficiently complementary to mRNA encoding Foxo1 to reduce its expression in an amount and under conditions that permit a portion of the population to produce insulin in a glucose-responsive manner, and
c) collecting the insulin-producing enteroendocrine cells.
14. The method of claim 13 , wherein the inhibitory oligonucleotide is selected from the group consisting of an antisense RNA, antisense DNA, and a chimeric antisense DNA/RNA.
15. The method of claim 13 , wherein the inhibitory oligonucleotide is selected from the group consisting of small interfering RNA (siRNA) and small hairpin RNA (shRNA).
16. The method of claim 13 , wherein the population is isolated from a segment of the intestine or colon.
17. The method of claim 16 , wherein the segment is taken from the duodenum or ileum and wherein the segment comprises crypts.
18. The method of claim 13 , further comprising reintroducing the insulin-producing enteroendocrine cells into the mammal in sufficient numbers to treat or prevent a disease or disorder.
19. The method of claim 13 , wherein the gut region is the duodenum, ileum or colon.
20. A method for treating Type I diabetes, the method comprising administering to the mammal a therapeutically effective amount of an inhibitory oligonucleotide that is sufficiently complementary to Foxo1 to reduce its expression, wherein administering comprises delivering the inhibitory oligonucleotide to enteroendocrine progenitor cells in the mammalian gut.
21. The method of claim 20 , wherein the inhibitory oligonucleotide is delivered by oral administration in an enteric form that releases the therapeutically effective amount onto a gut region comprising duodenum, ileum and/or colon or by local administration into or onto the duodenum, ileum and/or colon.
22. The method of claim 20 , wherein the inhibitory oligonucleotide is selected from the group consisting of an isolated small hairpin RNA (shRNA), small interfering RNA (siRNA), antisense RNA, antisense DNA, and chimeric antisense DNA/RNA.
23. A method for treating diabetes, the method comprising administering to the mammal a therapeutically effective amount of an inhibitory oligonucleotide that is sufficiently complementary to Foxo1 to reduce its expression, wherein administering comprises delivering the inhibitory oligonucleotide to enteroendocrine progenitor cells in the mammalian gut by oral administration in an enteric form that releases the therapeutically effective amount onto a gut region comprising duodenum, ileum and/or colon or by local administration into or onto the duodenum, ileum and/or colon.